Charleston News Online

DelveInsight Business Research LLP

Primary Sclerosing Cholangitis Overview

Primary sclerosing cholangitis is a rare cholestatic disorder of the liver, with strictures in the bile ducts leading to liver cirrhosis in a proportion of patients. The etiology of PSC is unknown; thus, generally considered an idiopathic disease, commonly associated with inflammatory bowel disease and increased risk of cholangiocarcinoma, gall bladder cancer, colorectal cancer, and hepatocellular carcinoma. Medical therapies are primarily aimed at symptom management, and disease-modifying therapies are limited. Endoscopic therapies are used in patients with dominant strictures, and liver transplantation is a last resort. The pathogenesis is believed to encompass genetic, chemical, environmental (including microbiome factors), and immunologic pathways that selectively damage the biliary epithelium with no specific single cause identified. Furthermore, cholangiography is the gold standard for the diagnosis of PSC. MRCP is the investigation of choice for diagnosis. MRCP avoids radiation and contrast media associated with endoscopic retrograde cholangiography (ERCP). However, MRCP provides suboptimal visualization of the intrahepatic bile ducts. Multifocal short segmental strictures are seen on MRCP, suggesting a ‘beads on string appearance’.

 Primary Sclerosing Cholangitis Epidemiological Insights 

• Primary Sclerosing Cholangitis is a rare disorder with regional variation in prevalence. The prevalence in the United States is estimated to be 1 to 16 per 100,000.

• An estimated 80% of patients diagnosed with Primary Sclerosing Cholangitis have concurrent IBD.

• According to Aune et al., 2021, a rare disease with an incidence of 0.4–0.7 cases per 100,000 in the UK and a prevalence of 3.9–16.2 per 100,000. 

• The total prevalent cases of primary sclerosing cholangitis were the highest in the United States, followed by Germany. Spain accounted for the least number of prevalent cases among the 7MM. 

 Learn how the market will evolve by 2032 @ Primary Sclerosing Cholangitis Market Trends ad Developments

 The Report Covers the Primary Sclerosing Cholangitis Epidemiology Segmented by – 

• Primary Sclerosing Cholangitis prevalent cases 

• Primary Sclerosing Cholangitis gender-based cases

Primary Sclerosing Cholangitis Therapeutics Market Outlook 

The report’s Primary Sclerosing Cholangitis market outlook helps understand historical, current, and forecasted Primary Sclerosing Cholangitis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology. It also covers the Primary Sclerosing Cholangitis market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the KOL.  According to DelveInsight, the Primary Sclerosing Cholangitis market in the 7MM + Nordic countries is expected to grow steadily during the study period (2019–2032).

Key Companies Working in the Primary Sclerosing Cholangitis Market Includes

• Gilead Sciences

• High Tide Pty Ltd

• NGM Biopharma

And many more 

Primary Sclerosing Cholangitis Therapies Covered and Analyzed in the Report:

• Cilofexor

• HTD1801

• NGM282 (Aldafermin) 

And many others 

Read more about the Key Companies and Emerging Therapies in the Primary Sclerosing Cholangitis Market 

Table of Contents

1. Key Insights 

2. Primary Sclerosing Cholangitis Introduction 

3. Executive Summary of Primary Sclerosing Cholangitis

4. Disease Background and Overview

5. Epidemiology and patient population

6. Primary Sclerosing Cholangitis Emerging Therapies

7. Primary Sclerosing Cholangitis Market Outlook

8. Market Access and Reimbursement of Therapies

9. Market Drivers 

10.  Market Barriers 

11.  Appendix

12. Report Methodology

13.  DelveInsight Capabilities

14.  Disclaimer

Learn more about the detailed offering of the report @ Primary Sclerosing Cholangitis Market Outlook 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services